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Background: Buddlejasaponin IV (BS-IV), a triterpene saponin isolated from Pleurospermum kamtschaticum HOFFMANN (Umbelliferae), 
is known to have potent anti-inflammatory activity and cytotoxicity against diverse cancer cell lines. In the present study, we 
attempted to verify whether BS-IV could inhibit cell growth, and induce cell cycle arrest and apoptosis in highly invasive YD-10B 
human oral squamous cell carcinoma (OSCC) cells. 
Methods: YD-10B cells were treated with various concentrations of BS-IV, and the cell viability was evaluated by MTT assay. Flow 
cytometry was conducted to examine cell phase distribution and DAPI staining was performed to observe apoptotic morphological 
changes in BS-IV-treated YD-10B cells. Western blot analysis was used to investigate the expression of proteins associated with cell 
cycle arrest and apoptosis.
Results: BS-IV treatment significantly reduced the viability of YD-10B cells and partially arrested cell cycle progression at the G2/M 
phase. Treatment with BS-IV substantially decreased the levels of cyclin B1 and stimulated the phosphorylation of checkpoint kinase 2 
(Chk2). The expression of p21 was increased but the phosphorylation of Akt was inhibited in BS-IV-treated YD-10B cells. Furthermore, 
BS-IV induced release of cytochrome c from mitochondria by reducing anti-apoptotic Bcl-2 level and increasing pro-apoptotic Bax level. 
Active caspase-3 level and the cleavage of poly (ADP-ribose) polymerase (PARP) were enhanced by BS-IV treatment. In addition, BS-IV 
increased the expression of Fas death receptor and its ligand (FasL) in YD-10B cells. 
Conclusions: The treatment with BS-IV inhibits the growth of YD-10B cells by inducing p21-dependent cell cycle arrest at G2/M phase 
and apoptosis through both mitochondrial-dependent and death receptor-mediated pathways. Thus, BS-IV is an excellent candidate for 
a chemopreventive agent to block the progression of human OSCC. (J Cancer Prev 2013;18:330-336)
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INTRODUCTION
  Oral squamous cell carcinoma (OSCC) is the most 
common malignant tumor of the oral cavity worldwide and 
consistently increasing in developing countries. OSCC is 
characterized by a high degree of local invasiveness and 
highly metastasize to the cervical lymph nodes.1,2 Despite 
recent improved clinical surgery and development of new 
anticancer drugs, OSCC has high mortality rate in patients 
with distant metastases. Therefore, the early diagnosis and 
standard treatments is extremely important to inhibit the 
onset and progression of oral carcinomas.3 Furthermore, 
alternative cancer therapy has been demanded for control 
OSCC and phytochemicals has been suggested as the major 
source for anticancer agents against a various malignant 
tumors. 
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Fig. 1. Chemical structure of BS-IV.
 Apoptosis, the programmed cell death, is critical for 
cellular homeostasis and is also one of the important 
mechanisms for the treatment of various cancers.4 The 
apoptotic process is induced by both death receptor 
(extrinsic) pathway and mitochondrial (intrinsic) pathway. 
The death receptor-mediated pathway involves the Fas, 
FasL and procaspase-8. The mitochondria-dependent 
pathway is controlled by members of Bcl-2 family, causing 
the release of cytochrome c from mitochondria and the 
activation of caspase cascade. Two main death pathways 
converge at caspase-3 activation, and then activated 
caspase-3 cleaves many substrate proteins including the 
DNA repair enzyme PARP.5
  Buddlejasaponin IV (BS-IV) (Fig. 1) is a major component 
of the aerial part of Pleurospermum kamtschaticum 
Hoffmann (Umbelliferae), and has been reported as potent 
anti-inflammatory agent inhibiting the production of nitric 
acid, prostaglandin E2, tumor necrosis factor-α and 
interleukin (IL)-1β as well as the expression of inducible 
nitric oxide synthase and cyclooxygenase-2 in lipopoly-
saccharide-stimulated RAW264.7 macrophages.6,7 BS-IV 
was also shown to evidence a remarkable hepatopro-
tective effect, antiviral activity and cytotoxicity against a 
panel of seven different cancer cell lines.8 In the previous 
study, we reported that BS-IV induces cell cycle arrest and 
apoptosis in human papillomaviruses infection-immor-
talized human oral keratinocytes.9
  The present study aimed to estimate the chemopreven-
tive potential of BS-IV against the highly invasive human 
OSCC cell line. We examined whether BS-IV could induce 
cell cycle arrest and apoptosis in YD-10B cells, and further 
explored the mechanism underlying its activity.
MATERIALS AND METHODS
1. Materials
  BS-IV was generously provided by Professor Hee-Juhn 
Park in Sangji University,6 dissolved in dimethyl sulfoxide 
(DMSO), stored at −20oC and further diluted with the 
culture medium. Highly invasive YD-10B human OSCC 
cells, which have been derived from tongue cancer tissues 
of patients, were obtained by Professor Jin Kim in Yonsei 
University College of Dentistry.10 DMEM: nutrient mixture 
F-12 (DMEM/F-12), fetal bovine serum (FBS), antibio-
tic-antimycotic (10,000 units/ml penicillin G sodium, 
10,000 μg/ml streptomycin sulfate and 25 μg/ml ampho-
tericin B), phosphate-buffered saline (PBS), and 0.25% 
trypsin-EDTA were purchased from Gibco BRL (Rockville, 
MD, USA). Cholera toxin, hydrocortisone, insulin, trans-
ferrin, triiodothronine (T3), 3-(4,5-Dimethylthiazol-2-yl) 
2,4-diphenyl tetrazolium bromide (MTT), RNase-A, Tween 
20, DMSO, propidum iodide (PI), 4’,6-diamidino-2- 
phenylindole (DAPI) and phenylmethylsulfonylfluoride 
(PMSF) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). The following antibodies were purchased from their 
respective sources: Bax, Bcl-2, PARP and caspase-3 (Cell 
Signaling Technology, Denver, MA, USA); GAPDH, cyto-
chrome c, Fas, FasL, cyclin B1, Cdc2, Cdk2, Cdc25C, Chk2, 
phospho-Chk2, p21, Akt, and phospho-Akt (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA); horseradish pero-
xidase (HRP)-conjugated secondary antibodies (Amersham 
Life Science, Little Chalfont, UK).
2. Cell culture
  YD-10B OSCC cells were grown in DMEM/F12 containing 
10% FBS, 1×10-10 M cholera toxin, 0.4 mg/ml hydro-
cortisone, 5 μg/ml insulin, 5 μg/ml transferrin and 2× 
10-11 M T3 at 37oC in a humidified atmosphere containing 
5% CO2.
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Fig. 2. BS-IV suppressed cell cycle progression in YD-10B cells. Cells were treated with 10 M BS-IV for 24 h, fixed in 70% 
ethanol and the nuclei were stained with PI. The percentages of cell phase distribution were analyzed by flow cytometry. Data 
are the representative of three independent experiments.
3. MTT assay
  YD-10B cells (5×103 cells/well) were plated into a 
96-well culture plate, and left overnight to adhere. The 
attached cells were treated with various concentrations of 
BS-IV for 24 and 48 h, respectively. Viable cells were 
detected using a 5 mg/ml MTT solution for an additional 4 
h at 37oC, followed by dissolving the produced formazan 
product in cells with 200 μl DMSO. Absorbance was 
measured at 570 nm using a Benchmark microplate reader 
(Bio-Rad, Hercules, CA, USA).
4. Cell cycle analysis
  YD-10B cells (4×105 cells/well) were treated with 10 μM 
BS-IV for 24 h. The cells were harvested, washed in cold 
PBS, fixed in 70% ethanol and stored at 4oC for 2 h. For DNA 
content analysis, the cells was treated with 0.25 mg/ml 
RNase-A for 30 min and stained with 50 μg/ml PI in 1.12% 
sodium citrate at room temperature. DNA content was 
analyzed by FACSCalibur using WinMDI 2.8 software (BD, 
Franklin Lakes, NJ, USA).
5. Western blot analysis
  YD-10B cells were treated with different concentrations 
of BS-IV for 24 h. The harvested cells were suspended in 
lysis buffer containing 50 mM Tris (pH 7.5), 1% NP-40, 2 
mM EDTA, 10 mM NaCl, 20 μg/ml aprotinin, 20 μg/ml 
leupeptin and 1 mM PMSF, and placed on ice for 30 min. 
After centrifugation at 12,000×g for 30 min at 4oC, the 
supernatant was collected, and then the protein concen-
tration in the supernatant was determined with a Bradford 
protein assay kit. Equal amounts of protein (50 μg) were 
loaded, separated on 10% SDS-polyacrylamide gels and 
transferred onto a polyvinylidene difluoride membrane 
(Millipore, Billerica, MA, USA). The membrane was blocked 
with 5% skim milk in PBS containing 0.1% Tween-20 and 
then incubated with specific primary antibody (1:1,000) 
against each protein overnight at 4oC. The blots were 
incubated with a 1:3,000 dilution of the respective 
HRP-conjugated secondary antibody for 2 h at room 
temperature. The target proteins were visualized with an 
enhanced chemiluminescence detection kit according to 
the protocol of the manufacturer (Amersham Life Science).
6. DAPI staining
  YD-10B cells (1×103 cells/well) were treated with 10 μM 
BS-IV for 24 h, washed twice with PBS and fixed in 4% 
paraformaldehyde. The cells were then stained with 1 μg/ml 
DAPI solution for 10 min at room temperature. The con-
densed or fragmented nuclei in apoptotic cells were ob-
served under a fluorescence microscope (Olympus, Tokyo, 
Japan). 
7. Cytochrome c release
  YD-10B cells, treated with BS-IV, were harvested and 
suspended in ice-cold buffer A (20 mM HEPES, 250 mM 
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Fig. 3. BS-IV regulated the expression of G2/M regulatory proteins in YD-10B cells. Cells were treated with the various doses 
of BS-IV for 24 h and total cell lysates were prepared. Cell cycle-related proteins (A), p21 (B), p-Akt and Akt (C) were analyzed 
by western blotting with the specific antibodies. Data are the representative of three independent experiments.
sucrose, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 
1 mM DTT, 1 mM PMSF, 10 μg/ml aprotinin and 5 μg/ml 
leupeptin, pH 7.5). The cells were passed through 
26-gauge needle 10 times, and then centrifuged at 750×g 
for 10 min at 4oC. The supernatant was twice centrifuged at 
12,000×g for 15 min 4oC, and the resulting supernatant 
was collected as the cytosolic fraction. The cytosolic 
fraction (50 μg protein) was electrophoresed on 12% SDS- 
polyacrylamide gels and analyzed by western blotting with 
a specific antibody against cytochrome c.
8. Statistical analysis
  Data were expressed as the means±standard deviation 
(SD) of three independent experiments and analyzed via 
one-way ANOVA with multiple comparisons using InStatTM 
statistical software (GraphPad Software, Inc., San Diego, 
CA, USA). P values of less than 0.05 were considered 
statistically significant.
RESULTS
1. BS-IV inhibits the viability of YD-10B OSCC cells
  When YD-10B human OSCC cells were cultured in 
serum-free medium with various concentrations of BS-IV, 
cell viability was dose- and time-dependently decreased 
(Data not shown). Its half maximal inhibitory concen-
tration (IC50) values were 22.5 μM for 24 h treatment and 
9.6 μM for 48 h treatment. 
2. BS-IV induces cell cycle arrest at G2/M phase in 
YD-10B OSCC cells
  We determined whether BS-IV could block cell cycle 
progression of YD-10B cells by flow cytometric analysis. 
When YD-10B cells were treated with 10 μM BS-IV for 24 
h, the percentage of YD-10B cells in the G2/M and S phase 
was slightly increased, but that in G0/G1 phase was 
decreased (Fig. 2). The cell cycle machinery is regulated by 
cyclins and Cdks, and the activities of the different 
cyclin-Cdk complexes modulate to control specific phases 
in the cell cycle. G2 to M phase progression is mainly 
controlled by the Cdc2-cyclin B1 complex, and Cdc25C 
phosphatase results in activation of Cdc2 by dephos-
phorylation.11 In addition, the phosphorylation of Chk2 
activates the G2 checkpoint.12,13 Western blot analysis 
indicated that the levels of cyclin B1 and Cdk2 were 
significantly decreased and the level of the phosphorylated 
Chk2 was dose-dependently enhanced in BS-IV-treated 
YD-10B cells (Fig. 3A). BS-IV treatment did not affect the 
levels of Cdc2 and Cdc25c. In addition, the increased p21 
protein level (Fig. 3B) and the reduced level of phospho-
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Fig. 4. BS-IV stimulation induced 
apoptotic morphological change of 
YD-10B cells. Cells were treated 
with 10M BS-IV for 24 h and 
stained with 1 μg/ml DAPI solu-
tion. The nuclei in apoptotic cells 
were observed under a fluores-
cence microscope. The morphology 
of cells was observed under bright 
field microscopy. Upper panel sho-
wed the cells under bright field mi-
croscope, lower panel showed the 
cells under fluorescence micro-
scope (×400 original magnifica-
tion). Data are the representative 
of three independent experiments.
Fig. 5. BS-IV regulated apoptotic proteins in YD-10B cells. Cells were treated with 1, 5 or 10 μM of BS-IV for 24 h. Total lysates 
and cytosolic fractions were prepared and electrophoresed on 10-12% SDS-polyacrylamide gel. The expression of Bax and Bcl2 
(A), cytosolic cytochrome c, caspase-3 and PARP (B), Fas and FasL (C) was detected by western blotting using specific antibodies. 
The data are representative of three independent experiments.
rylated Akt (Fig. 3C), which can directly phosphorylate p21 
and drop its level in nucleus,14 were observed in YD-10B 
cells treated with BS-IV for 24 h.
3. BS-IV induces apoptosis in YD-10B OSCC cells
  We further studied whether BS-IV could induce apoptosis 
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in YD-10B cells. BS-IV treatment for 24 h induced mor-
phological changes and apoptotic morphological changes 
were confirmed by DAPI staining (Fig. 4). The expression of 
Bax was increased and Bcl-2 level was reduced in 
BS-IV-treated cells (Fig. 5A). Consequently, BS-IV treat-
ment resulted in an increase in the Bax/Bcl-2 ratio, leading 
to the release of cytochrome c from mitochondria (Fig. 5B). 
Moreover, treatment with BS-IV elevated the level of active 
caspase-3 and induced the cleavage of PARP (Fig. 5B). 
Furthermore, BS-IV stimulation caused the increased 
expression of Fas and FasL (Fig. 5C).
DISCUSSION
  OSCC is particularly dangerous because of a high risk of 
producing secondary tumors and captures about 90% of 
overall oral cancers.2 Combination therapy of surgical and 
non-surgical approaches has been developed, but there 
has been no significant decline in the mortality rate over 20 
years due to a lack of markers for early prognosis and the 
failure of advanced tumors to respond to chemotherapy. In 
this study, we estimate whether BS-IV can be a promising 
candidate as a chemoprotective agent on OSCC. Human 
YD-10B cells are moderately differentiated squamouse cell 
carcinoma originated from tongue. YD-10B was charac-
terized as OSCC cells showing a sheet of polygonal cells 
scattered with dyskeratotic cells and has high tumori-
genicity and invasiveness. YD-10B cells typically expre-
ssed E-cadherin and EGFR, but did not express p53.15
  Cell growth is controlled by the rates of cell proliferation 
and cell death. In most cancer cells, abnormal proliferation 
is induced, but cell death and differentiation are inhibited. 
Therefore, the manipulation of the apoptotic process in 
cancer cells is a critical point for the removal of trans-
formed cells and preventing carcinogenesis. To elucidate 
YD-10B cell growth inhibition by BS-IV treatment, we 
investigated its effect on cell cycle progression and apop-
tosis. As a result, cell cycle was arrested at G2/M phase in 
BS-IV-treated YD-10B cells. 
  Next, we determined the molecular mechanism under-
lying cell cycle arrest and induction of apoptosis by BS-IV. 
Of cyclins and Cdks initiating entrance into M phase, BS-IV 
reduced expression of cyclin B1 and also increased the 
activation of Chk2, which are activated by ATM/ATR in 
response to DNA damage.16 Cyclin-Cdk complexes are 
regulated by Cdk inhibitors. Thus, the deregulated actions 
of the Cdk inhibitors contribute importantly to cancer 
development. In particular, p21 is targeted specifically to 
Cdc2 and Cdk2 complexes and regulated by Akt.17 Akt 
phosphorylates p21 Cdk inhibitor in the nucleus and 
exports them into the cytoplasm. Cytoplasmic p21 pro-
teins do not influence cyclin-Cdk complexes.14 BS-IV 
treatment induced p21 expression and suppressed the 
phosphorylation of Akt. These findings demonstrate that 
treatment with BS-IV may at least inhibit cell growth by 
cell cycle arrest at G2/M phase due to the reduced 
expression of cyclin B1 and Chk2 activation. BS-IV-in-
duced cell cycle arrest is closely associated with p53-inde-
pendent p21 expression.
  Apoptosis can be induced via the activation of the 
pro-apoptotic members of Bcl-2 family of proteins. In 
mitochondrial-dependent pathway, the increased pro- 
apoptotic Bcl-2-related proteins, particularly Bax, which 
antagonize the anti-apoptotic Bcl-2, favor cytochrome c 
release into cytosol through opening of the outer mito-
chondrial membrane.18 The released cytochrome c results 
in the activation of the caspase cascade and resultant 
cleavage of PARP for DNA repair.19 We found that BS-IV 
induced release of cytochrome c from mitochondria by 
reducing anti-apoptotic Bcl-2 level and increasing 
pro-apoptotic Bax level. In turn, active caspase-3 and 
PARP cleavage were significantly increased in BS-IV- 
treated YD-10B cells. Furthermore, BS-IV suppressed the 
expression of Fas death receptor and FasL. These results 
suggest that BS-IV may induce apoptosis by two distinct 
signaling pathways via mitochondria and death receptor in 
YD-10B cells.
  Collectively, the treatment with BS-IV inhibits the growth 
of YD-10B cells by inducing p21-dependent G2/M cell 
cycle arrest and apoptosis through both mitochon-
drial-dependent and death receptor-mediated pathways. 
BS-IV is an excellent candidate for a chemopreventive 
agent to block the progression of highly invasive OSCC. In 
addition, BS-IV has anti-inflammatory, anti-viral and 
anti-hepatotoxic activities as active compound of P. 
kamtschaticum traditionally used to treat various kinds of 
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disorders such as colds, arthritis, and impotence. Thus, 
BS-IV and the extracts with it may serve as beneficial 
supplement for health promotion. Furthermore, the evalu-
ation on bioavailability of BS-IV is determined.
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